

LIGAND PHARMACEUTICALS INC  
Form 425  
August 26, 2009

**Filed by Ligand Pharmaceuticals Incorporated**

**Pursuant to Rule 425 under the**

**Securities Act of 1933**

**Subject Company: Ligand Pharmaceuticals Incorporated**

**Commission File No: 001-33093**

**Contacts:**

Ligand Pharmaceuticals Incorporated

Lippert/Heilshorn & Associates

John L. Higgins, President and CEO or

Don Markley

Erika Luib, Investor Relations

dmarkley@lhai.com

(858) 550-7896

(310) 691-7100

**Ligand to Present at Thomas Weisel Partners on September 9**

**SAN DIEGO (August 26, 2009)** Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John L. Higgins, President and Chief Executive Officer will be presenting at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, at 9:10 a.m. Eastern time. The conference is being held at the Four Seasons Hotel in Boston.

A live webcast of the presentation will be available on Ligand's website at <http://investors.ligand.com/index.cfm>. A replay of the presentation will be archived on the site for 30 days.

**About Ligand Pharmaceuticals**

Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, Pfizer and Wyeth Pharmaceuticals. With nine pharmaceutical agreements and more than 20 molecules in various stages of development, Ligand utilizes proprietary technologies for identifying drugs with novel receptor and enzyme drug targets.

###